Phenoxybenzamine Hydrochloride — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	PO	0.25-1.5 mg/kg (initial 0.25 mg/kg, titrate up)	q8-12h	Duration: Variable; for pheochromocytoma, often lifelong; for urethral spasm, 3-7 days Notes: Start at low end and titrate based on blood pressure and clinical response. For pheochromocytoma, administer 10-14 days preoperatively to control blood pressure.
Cat	PO	0.5-2.5 mg/kg (usually 2.5-5 mg per cat)	q12-24h	Duration: 3-7 days for urethral spasm; long-term for pheochromocytoma Notes: Cats are sensitive; use lower doses initially. Monitor for hypotension and sedation.
Horse	IV	0.3-0.5 mg/kg diluted in saline, given slowly	Once or as needed	Duration: Short-term for acute laminitis Notes: Use with caution; monitor blood pressure closely. Not approved for horses.
Horse	PO	0.5-1.0 mg/kg	q12h	Duration: Variable Notes: Oral use is off-label; monitor for adverse effects.
Rabbit	PO	0.5-1.0 mg/kg	q12-24h	Duration: 3-5 days Notes: Limited data; use cautiously.

Clinical Indications & Species Uses

General Indications

Alpha-adrenergic blockade for management of pheochromocytoma
Reduction of urethral smooth muscle tone in urinary tract disorders

Dog (Canine)

Pheochromocytoma (preoperative management and long-term treatment)
Urethral obstruction due to functional urethral spasm
Hypertension associated with pheochromocytoma
Reflex dyssynergia (detrusor-urethral dyssynergia)
Mitral valve regurgitation (adjunctive therapy, though less common)

Cat (Feline)

Feline lower urinary tract disease (FLUTD) with urethral obstruction
Urethral spasm after relief of obstruction
Pheochromocytoma (rare)
Hypertension (off-label)

Horse (Equine)

Laminitis (adjunctive therapy to improve digital blood flow)
Post-operative ileus (off-label)
Pheochromocytoma (rare)

Rabbit & Small Mammals

Urethral obstruction (off-label)
Pheochromocytoma (rare)

Pharmacology & Mechanism of Action

Drug Class: Alpha-adrenergic blocking agent | Pharmacological Group: Irreversible non-selective alpha-1 and alpha-2 adrenergic antagonist

Mechanism of Action: Phenoxybenzamine hydrochloride is a long-acting, non-selective, irreversible alpha-adrenergic blocking agent. It forms a covalent bond with alpha-1 and alpha-2 adrenergic receptors, resulting in a permanent blockade that persists until new receptors are synthesized. The primary therapeutic effect is the relaxation of smooth muscle in blood vessels and other tissues, leading to vasodilation, decreased peripheral vascular resistance, and increased blood flow. In the urinary tract, it reduces urethral smooth muscle tone, which is beneficial in conditions like urethral obstruction or feline lower urinary tract disease. It also has some antihistaminic and antiserotonergic activity.

Pharmacodynamics: Phenoxybenzamine produces a dose-dependent blockade of alpha-adrenergic receptors. The onset of action is gradual, with maximal effect typically seen within 1-2 hours after oral administration, but the full therapeutic effect may take several days to develop due to the irreversible nature of the blockade. The duration of action is prolonged, often lasting 24-48 hours or longer. It causes a decrease in blood pressure, reflex tachycardia, and increased cardiac output. In the urinary system, it reduces urethral pressure and resistance, facilitating urine flow. It does not affect beta-adrenergic receptors, so bronchodilation and cardiac stimulation are not prominent.

⚡ Pharmacokinetics Summary

Absorption: Phenoxybenzamine is well absorbed after oral administration, but its bioavailability is variable due to extensive first-pass metabolism. Peak plasma concentrations occur within 1-2 hours. The drug is also available as an injectable solution for intravenous use, which provides rapid onset of action.

Distribution: Phenoxybenzamine is highly lipophilic and distributes widely throughout the body. It accumulates in adipose tissue and is extensively bound to plasma proteins (approximately 90%). It crosses the blood-brain barrier and placenta, and is excreted in milk.

Metabolism: Phenoxybenzamine undergoes extensive hepatic metabolism, primarily via oxidative deamination and O-demethylation. The metabolites are mostly inactive, but some may retain alpha-blocking activity. The irreversible binding to receptors contributes to its long duration of action.

Excretion: Metabolites are excreted primarily in the urine (about 50%) and bile (about 50%). The elimination half-life is approximately 24 hours in dogs, but the pharmacodynamic effect lasts much longer due to irreversible receptor binding.

Half-Life: Dogs: approximately 24 hours; Cats: not well documented, but similar to dogs; Horses: approximately 6-8 hours.

Bioavailability: Oral bioavailability is variable, estimated at 20-50% due to first-pass metabolism.

Protein Binding: Approximately 90% bound to plasma proteins.

Available Formulations & Strengths

Oral Capsule 10 mg (PO)

Injectable Solution 50 mg/mL (5 mL vial) (IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to phenoxybenzamine or any component
Hypotension or shock
Severe cardiovascular disease (e.g., congestive heart failure, recent myocardial infarction)
Concurrent use with epinephrine or norepinephrine (may cause severe hypotension and tachycardia)
Use in animals with renal impairment (caution)

Warnings & Clinical Precautions:

May cause marked hypotension, especially in dehydrated or hypovolemic animals; ensure adequate hydration before administration.
Use with caution in animals with cerebral or coronary insufficiency.
May cause reflex tachycardia; monitor heart rate.
In cats, may cause mydriasis and increased sensitivity to light.
In horses, may cause severe hypotension; use only with careful monitoring.
Not for use in pregnant or lactating animals unless benefits outweigh risks.
Administer with food to reduce gastrointestinal upset.
Monitor blood pressure and heart rate during dose titration.

Adverse Effects & Reactions

Common:

Hypotension
Reflex tachycardia
Nasal congestion
Miosis (in some species)
Gastrointestinal upset (vomiting, diarrhea)
Sedation or lethargy
Mydriasis (in cats)

Serious / Severe:

Severe hypotension leading to shock
Arrhythmias (tachyarrhythmias)
Cerebral or myocardial ischemia
Paradoxical hypertension (in pheochromocytoma cases if alpha blockade is incomplete)

Rare:

Allergic reactions (urticaria, angioedema)
Bone marrow suppression
Hepatotoxicity
Prolonged QT interval

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Epinephrine or norepinephrine	Phenoxybenzamine blocks alpha receptors, leaving beta effects unopposed, leading to severe hypotension and tachycardia (epinephrine reversal).	High
Other antihypertensives (e.g., ACE inhibitors, calcium channel blockers)	Additive hypotensive effects.	Moderate
Beta-blockers (e.g., propranolol)	May cause unopposed alpha-mediated vasoconstriction, leading to hypertension.	Moderate
Sympathomimetic amines (e.g., dopamine, dobutamine)	Reduced pressor response; may require higher doses.	Moderate
Anesthetics (e.g., halothane)	Increased risk of arrhythmias and hypotension.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Severe hypotension
Tachycardia
Arrhythmias
Shock
Lethargy or collapse
Mydriasis
Gastrointestinal signs (vomiting, diarrhea)

Emergency Treatment Protocol: Treatment is symptomatic and supportive. Discontinue the drug immediately. Administer intravenous fluids (e.g., lactated Ringer's) to maintain blood pressure. If severe hypotension persists, consider vasopressors such as norepinephrine (but note that alpha blockade may reduce its efficacy; use with caution). Monitor cardiac function and treat arrhythmias as needed. In cases of recent oral ingestion, consider gastric lavage or activated charcoal if within 1-2 hours. Provide supportive care and monitor vital signs closely.

Food Animal Withdrawal Times

Not approved for use in food animals. If used off-label in food animals, a prolonged withdrawal period (e.g., 30 days for meat and 7 days for milk) is recommended, but due to lack of data, it is safer to avoid use in food animals.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature (20-25°C, excursions permitted to 15-30°C).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep container tightly closed.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (Dibenzyline).

Extra-Label (Off-Label) Use: In the US, phenoxybenzamine is not FDA-approved for veterinary use; it is used extra-label under the Animal Medicinal Drug Use Clarification Act (AMDUCA). For food animals, extra-label use is prohibited if an approved animal drug exists that is labeled for the condition and contains the same active ingredient. Since no approved veterinary product exists, extra-label use is permitted only with a valid veterinary-client-patient relationship and appropriate withdrawal times.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Phenoxybenzamine is a valuable drug for managing pheochromocytoma and functional urethral obstruction in small animals. Its irreversible alpha-blockade provides sustained effects, but careful dose titration is essential to avoid severe hypotension. In dogs with pheochromocytoma, it is used preoperatively to control blood pressure and reduce surgical risk. In cats with urethral obstruction, it helps relax the urethra and prevent re-obstruction. It is not a first-line treatment for hypertension in general. Use with caution in animals with cardiovascular disease, and monitor blood pressure and heart rate during therapy. Due to its long duration of action, adverse effects may persist for 24-48 hours after discontinuation. Always consider the risk-benefit ratio and use the lowest effective dose.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)